RecruitingPhase 2NCT07391241
A Phase 2 Study to Evaluate the Efficacy and Safety of Pudafensine in Vulvodynia (Provoked Vestibulodynia)
A Randomised, Double-blind, Placebo-controlled, 4-way Cross-over Trial Studying the Efficacy and Safety of Single Dose Administration of Pudafensine in Vulvodynia (Provoked Vestibulodynia).
Sponsor
Initiator Pharma
Enrollment
24 participants
Start Date
Dec 17, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The study (IP2015CS05) is a randomised, double-blind, placebo-controlled, 4-way cross-over trial studying the efficacy and safety of single dose administration of pudafensine in vulvodynia (provoked vestibulodynia) patients.
Eligibility
Sex: FEMALEMin Age: 18 YearsMax Age: 65 Years
Inclusion Criteria1
- Participant with vulvodynia (provoked vestibulodynia).
Exclusion Criteria13
- Women with vulvar pain caused by a specific disorder:
- Infectious (e.g. recurrent candidiasis, herpes).
- Inflammatory (e.g. lichen sclerosus, lichen planus, immunobullous disorders).
- Neoplastic (e.g. Paget disease, squamous cell carcinoma).
- Neurologic (e.g. postherpetic neuralgia, nerve compression or injury, neuroma).
- Trauma (e.g. female genital cutting, obstetrical).
- Iatrogenic (e.g. postoperative, chemotherapy, radiation).
- Hormonal deficiencies (e.g. genitourinary syndrome of menopause (vulvovaginal atrophy), lactational amenorrhea).
- History or current diagnosis of significant pelvic floor dysfunction.
- Co-morbid pelvic pain conditions including pain due to pelvic fractures, pelvic girdle pain or post-partum pelvic pain (to avoid confounding pain outcomes).
- History or current diagnosis of pelvic inflammatory disease.
- History or current diagnosis of endometriosis.
- History or current diagnosis of interstitial cystitis.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGPudafensine
Pudafensine
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07391241
Related Trials
Topical Ketotifen 0.25% for Secondary Vestibulodynia
NCT072570293 locations
Prospective Data Bank Creation to Study Vaginal Conditions
NCT018292041 location
Young Vulvodynia: Effect and Efficacy of Multimodal Treatment.
NCT070923321 location
Biomodulation and Rehabilitation Interventions to TarGet Pelvic Health
NCT066602122 locations
Vestibulodynia At High Resolution: Omics Approach to Improve Diagnosis
NCT068659631 location